Clinical TrialsSearch results
Number of results: 253
Other
- 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
- Neuroblastoma
- Tomita Koji
- 2020-10-21
Other
- A feasibility study of accelerated partial breast irradiation using interstitial brachytherapy for female breast cancer <=3cm pN0M0
- breast cancer
- Oguchi Group, Grant for Cancer Research, Ministry of Health, Labour, and Welfare
- 2009-02-01
Other
- A late phase II study of multidisciplinary approach to establish standard treatment for advanced neuroblastoma
- neuroblastoma
- Japan Neuroblastoma Study Group
- 2008-02-20
Other
- A Multi-Center, Prospective Study of Covered WallFlex Biliary Metallic Stent for extrahepatic malignant biliary obstruction
- Malignant biliary obstruction
- Faculty of Medicine, University of Tokyo
- 2009-08-08
Other
- A multicenter study on warfarin use and optimal anticoagulation levels for prevention of cardiogenic embolism in Japanese patients with atrial fibrillation: J-RHYTHM Registry
- atrial fibrillation
- The Japanese Society of Electrocardiology
- 2009-01-05
Other
- A multicentre study on clinical usefulness of urinary trypsinogen-2 for early diagnosis of acute pancreatitis.
- Definite or possible acute pancreatitis.
- Division of Gastroenterology, Tohoku University Graduate School of Medicine
- 2009-01-07
Other
- A non-randomized confirmatory study of Limited Surgical Resection for Peripheral Early Lung Cancer Defined with Thoracic Thin-section Computed Tomography (JCOG0804/WJOG4507L)
- small (2 cm or less) peripheral radiological non-invasive lung cancer
- Japan Clinical Oncology Group(JCOG)
- 2009-05-26
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Sulfonylurea
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2009-04-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Thiazolidine
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2008-10-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to an Alpha-Glucosidase Inhibitor
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2008-10-01